The epigenetically regulated effects of wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24)

DNA and Cell Biology

Volumn 33, Issue 7, 2014, Pages 408-417

  Varol, Nuray ^a   Konac, Ece ^a   Onen, Ilke Hacer ^a   Gurocak, Serhat ^a   Alp, Ebru ^a   Yilmaz, Akin ^a   Menevse, Sevda ^a   Sozen, Sinan ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CYCLIN D1; DEOXYCYTIDINE; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; PROTEIN BCL 2; TRICHOSTATIN A; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D; CYTIDINE TRIPHOSPHATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; HYDROXAMIC ACIDS; URINARY BLADDER NEOPLASMS; WNT PROTEINS;

EID: 84903275258     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2013.2285     Document Type: Article

References (36)

1. Ahmad, I., Patel, R., Liu, Y., Singh, L.B., Taketo, M.M., Wu, X.R., Leung, H.Y., and Sansom, O.J. (2011). Ras mutation cooperates with b-catenin activation to drive bladder tumourigenesis. Cell Death Dis 2, e124.
2. Ai, L., Tao, Q., Zhong, S., Fields, C.R., Kim, W.J., Lee, M.W., Cui, Y., Brown, K.D., and Robertson, K.D. (2006). Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27, 1341-1348. (Pubitemid 43985409)
3. Alao, J.P., Stavropoulou, A.V., Lam, E.W., Coombes, R.C., and Vigushin, D.M. (2006). Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer 5, 8.
4. Azechi, T., Kanehira, D., Kobayashi, T., Sudo, R., Nishimura, A., Sato, F., and Wachi, H. (2013). Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. J Atheroscler Thromb 20, 538-547.
5. Charlet, J., Schnekenburger, M., Brown, K.W., and Diederich, M. (2012). DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochem Pharmacol 83, 858-865.
6. Costa, V.L., Henrique, R., Ribeiro, F.R., Carvalho, J.R., Oliveira, J., Lobo, F., Teixeira, M.R., and Jerónimo, C. (2010). Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics 5, 343-351.
7. da Silva, G.N., de Castro Marcondes, J.P., de Camargo, E.A., da Silva Passos Júnior, G.A., Sakamoto-Hojo, E.T., and Salvadori, D.M. (2010). Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med 235, 814-824.
8. Diehl, J.A., Zindy, F., and Sherr, C.J. (1997). Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11, 957-972. (Pubitemid 27199876)
9. DiPaola, R.S., Rubin, E., Toppmeyer, D., Eid, J., Butzbach, D., Dvorzhinski, D., Capanna, T., Cairdella, M., Shih, J.W., Goodin, S., and Todd, M.B. (2003). Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. Med Sci Monit 9, PI5-11.
10. Dokmanovic, M., Clarke, C., and Marks, P.A. (2007). Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5, 981-989. (Pubitemid 350080267)
11. Enokida, H., and Nakagawa, M. (2008). Epigenetics in bladder cancer. Int J Clin Oncol 13, 298-307.
12. Foti, S.B., Chou, A., Moll, A.D., and Roskams, A.J. (2013). HDAC inhibitors dysregulate neural stem cell activity in the postnatal mouse brain. Int J Dev Neurosci 31, 434-447.
13. Gallagher, D.J., Milowsky, M.I., and Bajorin, D.F. (2008). Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 113, 1284-1293.
14. Gao, Z., Xu, Z., Hung, M.S., Lin, Y.C., Wang, T., Gong, M., Zhi, X., Jablon, D.M., and You, L. (2009). Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells. Anticancer Res 29, 2025-2030.
15. He, B., Reguart, N., You, L., Mazieres, J., Xu, Z., Lee, A.Y., Mikami, I., McCormick, F., and Jablons, D.M. (2005). Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24, 3054-3058. (Pubitemid 40675537)
16. Jeon, H.G., Yoon, C.Y., Yu, J.H., Park, M.J., Lee, J.E., Jeong, S.J., Hong, S.K., Byun, S.S., and Lee, S.E. (2011). Induction of caspase mediated apoptosis and down-regulation of nuclear factor-kB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells. J Urol 186, 2084-2093.
17. Kawakami, K., Hirata, H., Yamamura, S., Kikuno, N., Saini, S., Majid, S., Tanaka, Y., Kawamoto, K., Enokida, H., Nakagawa, M., and Dahiya, R. (2009). Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 69, 8603-8610.
18. Kawano,Y., and Kypta, R. (2003). Secreted antagonists of theWnt signalling pathway. J Cell Sci 116(Pt 13):2627-2634.
19. Li, J., Ying, J., Fan, Y., Wu, L., Ying, Y., Chan, A.T., Srivastava, G., and Tao, Q. (2010). WNT5A antagonizes WNT/bcatenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther 10, 617-624.
20. Luo, J., Chen, J., Deng, Z.L., Luo, X., Song, W.X., Sharff, K.A., Tang, N., Haydon, R.C., Luu, H.H., and He, T.C. (2007). Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 87, 97-103.
21. Luu, H.H., Zhang, R., Haydon, R.C., Rayburn, E., Kang, Q., Si, W., Park, J.K., Wang, H., Peng, Y., Jiang, W., and He, T.C. (2004). Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 4, 653-671. (Pubitemid 40013572)
22. Naito, S., Bilim, V., Yuuki, K., Ugolkov, A., Motoyama, T., Nagaoka, A., Kato, T., and Tomita, Y. (2010). Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res 16, 5124-5132.
23. Park, H.J., Kim, H.J., Bae, G.S., Seo, S.W., Kim, D.Y., Jung, W.S., Kim, M.S., Song, M.Y., Kim, E.K., Kwon, K.B., Hwang, S.Y., Song, H.J., Park, C.S., Park, R.K., Chong, M.S., and Park, S.J. (2009). Selective GSK-3beta inhibitors attenuate the cisplatin-induced cytotoxicity of auditory cells. Hear Res 257, 53-62.
24. Paul, S., and Dey, A. (2008). Wnt signaling and cancer development: therapeutic implication. Neoplasma 55, 165-176.
25. Shang, D., Liu, Y., Matsui, Y., Ito, N., Nishiyama, H., Kamoto, T., and Ogawa, O. (2008). Demethylating agent 5-aza-2¢- deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. Urology 71, 1220-1225. (Pubitemid 351763776)
26. Shiina, H., Igawa, M., Breault, J., Ribeiro-Filho, L., Pookot, D., Urakami, S., Terashima, M., Deguchi, M., Yamanaka, M., Shirai, M., Kaneuchi, M., Kane, C.J., and Dahiya, R. (2003). The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res 9, 2121-2132. (Pubitemid 36687634)
27. Steinhusen, U., Badock, V., Bauer, A., Behrens, J., Wittman- Liebold, B., Dörken, B., and Bommert, K. (2000). Apoptosisinduced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem 275, 16345-16353. (Pubitemid 30366951)
28. Suzuki, H., Toyota, M., Carraway, H., Gabrielson, E., Ohmura, T., Fujikane, T., Nishikawa, N., Sogabe, Y., Nojima, M., Sonoda, T., Mori, M., Hirata, K., Imai, K., Shinomura, Y., Baylin, S.B., and Tokino, T. (2008). Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98, 1147-1156. (Pubitemid 351399804)
29. Tang, Y., Simoneau, A.R., Liao, W.X., Yi, G., Hope, C., Liu, F., Li, S., Xie, J., Holcombe, R.F., Jurnak, F.A., Mercola, D., Hoang, B.H., and Zi, X. (2009). WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther 8, 458-468.
30. Urakami, S., Shiina, H., Enokida, H., Kawakami, T., Tokizane, T., Ogishima, T., Tanaka, Y., Li, L.C., Ribeiro-Filho, L.A., Terashima, M., Kikuno, N., Adachi, H., Yoneda, T., Kishi, H., Shigeno, K., Konety, B.R., Igawa, M., and Dahiya, R. (2006). Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 12, 383-391. (Pubitemid 43166125)
31. von der Maase, H., Hansen, S.W., Roberts, J.T., Dogliotti, L., Oliver, T., Moore, M.J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C.M., Kerbrat, P., Sanchez Rovira, P., Wersall, P., Cleall, S.P., Roychowdhury, D.F., Tomlin, I., Visseren-Grul, C.M., and Conte, P.F. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18, 3068-3077.
32. Witt, O., Deubzer, H.E., Milde, T., and Oehme, I. (2009). HDAC family: what are the cancer relevant targets? Cancer Lett 277, 8-21.
33. Yeh, C.T., Yao, C.J., Yan, J.L., Chuang, S.E., Lee, L.M., Chen, C.M., Yeh, C.F., Li, C.H., and Lai, G.M. (2011). Apoptotic cell death and inhibition of Wnt/b-catenin signaling pathway in human colon cancer cells by an active fraction (HS7) from Taiwanofungus camphoratus. Evid Based Complement Alternat Med [Epub ahead of print]; DOI:10.1155/2011/750230.
34. Yoon, C.Y., Park, M.J., Lee, J.S., Lee, S.C., Oh, J.J., Park, H., Chung, C.W., Abdullajanov, M.M., Jeong, S.J., Hong, S.K., Byun, S.S., Lee, E.S., and Lee, S.E. (2011). The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line. J Urol 185, 1102-1111.
35. Yu, X., Wang, Y., DeGraff, D.J., Wills, M.L., and Matusik, R.J. (2011). Wnt/b-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30, 1868-1879.
36. Yun, S.I., Yoon, H.Y., and Chung, Y.S. (2009). Glycogen synthase kinase-3beta regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells. Apoptosis 14, 771-777.